- Molecular Genetics Core Given the value of model organisms and molecular genetic tools for the study of diabetes and its co- morbidities, the Molecular Genetics Core (MGC) is designed to aid diabetes researchers in the development of novel rodent models and molecular tools to determine the cellular and molecular mechanisms contributing to diabetes. Established in 2015, the MGC is a fee-for-service core that facilitates the application of molecular genetic methods to diabetes-related research. Specifically, the MGC (1) designs and produces genetically- modified rodent models (using CRISPR/Cas9) for use in diabetes-related research; (2) designs and produces AAV vectors for use in diabetes research; (3) produces and provides specialty viral reagents for use in diabetes research; and (4) provides advice and training in the use of these technologies to members of MDRC laboratories. The MG Core also owns and maintains several pieces of shared equipment for the use of MDRC members located at different sites around the UM medical campus. While CRISPR/Cas9 technology has dramatically increased the speed and decreased the cost at which such models can be generated, the pace at which this new technology continues to evolve prevents many diabetes researchers from taking full advantage of its potential. The MGC fills this gap by using its expertise and personnel to design and construct CRISPR/Cas9 targeting reagents, collaborate with the UM Transgenic Core to test these reagents in embryos and produce founder mice, and identify founders for transfer (along with genotyping protocols) to the MDRC investigator. For the generation of viral reagents, the MGC designs and produces any necessary constructs, which are packaged into viruses by the UM Viral Vector Core. With input from MDRC members and the MGC advisory committee, the MGC also identifies and develops new technologies (viral and genetic) in support of the research programs of MDRC members.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Center Core Grants (P30)
Project #
2P30DK020572-41
Application #
9443256
Study Section
Special Emphasis Panel (ZDK1)
Project Start
Project End
Budget Start
2018-02-27
Budget End
2018-11-30
Support Year
41
Fiscal Year
2018
Total Cost
Indirect Cost
Name
University of Michigan Ann Arbor
Department
Type
DUNS #
073133571
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Sas, Kelli M; Lin, Jiahe; Rajendiran, Thekkelnaycke M et al. (2018) Shared and distinct lipid-lipid interactions in plasma and affected tissues in a diabetic mouse model. J Lipid Res 59:173-183
Adams, Jessica M; Pei, Hongjuan; Sandoval, Darleen A et al. (2018) Liraglutide Modulates Appetite and Body Weight Through Glucagon-Like Peptide 1 Receptor-Expressing Glutamatergic Neurons. Diabetes 67:1538-1548
Fernandez, Carmen; DeJesus, Jasmine M; Miller, Alison L et al. (2018) Selective eating behaviors in children: An observational validation of parental report measures. Appetite 127:163-170
Zhang, Sherry; Lu, Chunxia; Das, Arun K et al. (2018) Abrogation of GH action in Kupffer cells results in increased hepatic CD36 expression and exaggerated nonalcoholic fatty liver disease. Growth Horm IGF Res 42-43:74-79
Mishra, Manish; Duraisamy, Arul J; Kowluru, Renu A (2018) Sirt1: A Guardian of the Development of Diabetic Retinopathy. Diabetes 67:745-754
Jaiswal, Mamta; Divers, Jasmin; Urbina, Elaine M et al. (2018) Cardiovascular autonomic neuropathy in adolescents and young adults with type 1 and type 2 diabetes: The SEARCH for Diabetes in Youth Cohort Study. Pediatr Diabetes 19:680-689
Rios, Peter D; Skoumal, Michael; Liu, Jeffrey et al. (2018) Evaluation of encapsulating and microporous nondegradable hydrogel scaffold designs on islet engraftment in rodent models of diabetes. Biotechnol Bioeng 115:2356-2364
Zhang, Peng; Kuang, Henry; He, Yanlin et al. (2018) NRG1-Fc improves metabolic health via dual hepatic and central action. JCI Insight 3:
Rosenstock, Julio; Perkovic, Vlado; Alexander, John H et al. (2018) Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA®): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardi Cardiovasc Diabetol 17:39
Kady, Nermin M; Liu, Xuwen; Lydic, Todd A et al. (2018) ELOVL4-Mediated Production of Very Long-Chain Ceramides Stabilizes Tight Junctions and Prevents Diabetes-Induced Retinal Vascular Permeability. Diabetes 67:769-781

Showing the most recent 10 out of 1823 publications